Ultrasound Characteristics of Breast Changes in Albanian Postmenopausal Women Who use Hormonal Replacement Therapy

Albana SHAHINI Ph.D, Erinda KOSTURI M.D.

Abstract: Background: HRT has been widely used in Albania, but it seems its importance has been raising lately. Many women are opting for this treatment as soon as menopause onset is diagnosed. It wasn’t until later that, gynecologist started referring women for regular breast ultrasound after hormonal replacement therapy began. The aim of this study was identifying changes in breasts of postmenopausal women who had been under HRT, using sonography. Materials: This is a retrospective study, based on data gathered from women who were referred to us by gynecologist. All women were under cyclic regimen HRT. From all 165 women, only data for 150 patients are included in this report. The 15 women excluded from the study, had either insufficient records or had been diagnosed with suspicious lesions since the first visit and were sent for further investigation. Once a year, for 6 consecutive years, breast ultrasonography was performed, and lesions were described using BIRAD-S lexicon. Patient’s data were completed with careful anamnestic details time after time, and with hormonal and biochemical analysis. Results: After HRT, we noticed that breast glandular section thickness had increased while breast ducts had become smaller. We were able to identify solid breast lesion ex novo in 8.7% and cysts in 2%. Reported serum estradiol levels in the 3rd year were quite higher in women who had marked structural changes opposed to the ones who didn’t experience such morphological change. These differences were significant in the 6th year of therapy. Conclusions: Starting HRT, leads to many changes in breast structure, which afterward need careful sonography assessment. An increasing percentage of the glandular tissue was reported from the first examinations until the 6th year. In subjects with such change we can also identify breast solid lesions or cysts. Therefore, we recommend annual follow-ups in all women, specially if under HRT.

Keywords: ultrasound, breast, postmenopausal, BIRAD-S4

1. Introduction

At approximately 45 y.o., women reach a phase known as climacteric or colloquially. Every change that characterised their organism, during childhood-puberty transition, when hormonal flow stimulated the sexual characteristics- in order to reach the peak of sexual capacity and fertility- will be reversed. But, as the first part of the physical features are found in all mammals, the cessation of female reproductive capability, is a feature that belongs to humans only. While climacteric is a time period, that lasts for years, the end of the fertility is a single event, known as menopause, or the last menstruation of a women’s life.

Every single women will face such biologically predetermined phase, around 45-55 y.o. Nowadays, gynecologists and many other doctors, have to deal with this condition, but it wasn’t many years before, that this age did not attract such attention. During the Bronze age, for example, only about 7%, of women reached the climacteric age, meanwhile it is estimated that about 95% of women in the same countries, reach menopause. On average, women are likely to live 30 years beyond the moment menopause iniciates. At this times, we are giving these women a mean life expectancy of around 80 years, which on the other hand, has brought with it a rising number of severe health problems, not a few of which are directly related to the natural decrease of female sex hormones. At this point securing a total physical and mental wellness, has become an imperative for doctors.

This need of such wellness, is why more and more women opt for hormonal replacement therapy. Under HRT, women need careful screening of all biochemical parameters and mostly periodical breast sonographic assessment.

2. Materials and Methods

This is a retrospective study, of 165 women, referred to us for breast ultrasonography. All women were under hormonal replacement therapy, after menopause had been diagnosed. Careful and detailed anamnesis was provided for all women before the ultrasound was performed, including menarche age, menstrual cycles, number of pregnancies, abortions and miscarriages, breastfeeding period. For all women, for which there were available breast imaging from before the HRT initiation, the radiologist noticed if any changes were present.

From the group of 165 women, 13 were excluded from the final group because of lack of follow up documentation and 2 of them, because were classified as BIRAD-S 4 and were refered for mammo exam and histological examination. They were both found to be adenocarcinomas.

From the moment that HRT was prescribed, all 150 women, once a year for the next 6 years under treatment, were sonographically followed and underwent mammography as part of the recommended protocol when needed.

During ultrasound, datas regarding the breast were carefully gathered and described. When lesions were present, they were characterised using the BIRAD-S lexicon. In collaboration with gynecologist, records of patients, were completed with hormonal lab results and biochemical analysis. In addition, any other pain or tension felt in the breasts was documented.
3. Results

In the first sonographic assessment, at least a benign lesion was identified in 6.6% of the women screened. 8 of them, or 5.3% had fibroadenomas, which measured at maximum 20.4x13.6 mm, mostly localised at the inferior lateral quadrant region. 2 of the patients, or 1.3% of the women screened had cysts at the beginning of the treatment, which at maximum measure 8.7x4.4 mm, which met sonographic criteria of benign cysts, liquid filled, posterior acoustic enhancement and well defined borders.

During follow up, in the second year of HRT, pre-existent fibroadenomas, had undergone an increase in diameters of about 9.9x4.9 mm whereas the cysts an increase in diameter of approximately 8.5x4.3 mm. In the third year of check-ups, 8.7% of the patients, or 13 women, had new solid lesions, and 2% or 3 women, had new cysts. Sonographic examinations, pointed a thickness of the glandular tissues, which showed that HRT delayed the normal physiological development of adipous tissue of breast.

In collaboration with gynecologist who referred these patients, charts were updated, and laboratoric parameters were noted. High levels of estradiol were present mostly in women who had distinct changes in the breasts compared to those with mild changes, or no changes at all. The sixth year of treatment showed the highest levels of breast changes. Mastodynia was present and more severe in all women with increased levels of estradiol and therefore the ones with structural changes as well.

4. Conclusions

Sonography, is one the finest methods, easily accessible and low cost used to screen for and early diagnose breast disease. It’s importance amplifies in women who undergo HRT. Literature, shows a moderate increase in risk of breast cancer development in all women under HRT, which increases by 2.3% per every year of HRT use, which gradually decreases therapy cessation. Starting a HRT, as reported above, leads to important changes in the breast structure, which implies the need of careful sono graphic assessment.

In this study, this potential risk, was shown by ex novo lesions: of which 8.7% were diagnosed as solid lesions, or fibroadenomas, and 2% cysts. Under sonographic guidance, we identified changes in the breast tissues during a 6 year follow-up. All patients, in which the changes in the glandular tissues was important, had a higher estrogen level. Both these changes, accompanied mastodynia. In conclusion, even though the study group represented above, was modest, our findings emphasise the importance of ultrasound examination in diagnosing early breast lesions in women receiving HRT, thus we firmly underline the importance of ultrasonography in diagnosis and follow-up of women under HRT especially.

References


Author Profile


Volume 3 Issue 6, June 2014
www.ijsr.net
Licensed Under Creative Commons Attribution CC BY